Oesophageal Cancer
80
17
21
25
Key Insights
Highlights
Success Rate
76% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
8 terminated out of 80 trials
75.8%
-10.7% vs benchmark
9%
7 trials in Phase 3/4
8%
2 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (80)
Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Cancer Loyalty Card Study 2 (CLOCS-2)
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
The PLATON Network
AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)
REVOLUTION Surgery (REVOLUTION Surgery)
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Esophageal Self-expandable Metal Stent for Malignant Strictures: a Safety and Efficacy Study
Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
Use of Different Enteral Feeds to Impact on Chyle Leaks in Oesophagectomy
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Cardiopulmonary Toxicity of Thoracic Radiotherapy
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)